SecurityTGXSF / Tigenix Sa
InstitutionMillennium Management Llc
ManagerIsrael Englander
Shares62,429
Value $ 1,430,000

Millennium Management Llc reports 1.50% decrease in ownership of TGXSF / Tigenix Sa

February 14, 2018 - Millennium Management Llc has filed a 13F-HR form disclosing ownership of 62,429 shares of Tigenix Sa (OTC:TGXSF) with total holdings valued at $1,430,000 USD as of December 31, 2017. Millennium Management Llc had filed a previous 13F-HR on November 14, 2017 disclosing 63,377 shares of Tigenix Sa at a value of $1,509,000 USD. This represents a change in shares of -1.50 percent and a change in value of -5.24 percent during the quarter.

Other investors with positions similar to Millennium Management Llc include Hillhouse Capital Management, Ltd., and Jane Street Group, Llc.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2017-12-31 13F-HR TIGENIX SPONSORED ADS 88675R109 23.36 62,429 -1.50 1,430 -5.24 -22 -57 -3.77
2017-09-30 13F-HR TIGENIX SPONSORED ADS 88675R109 23.18 63,377 -6.13 1,509 -0.92 -96 82 5.38
2017-06-30 13F-HR TIGENIX SPONSORED ADS 88675R109 19.08 67,513 -8.86 1,523 31.75 -125 492 42.58
2017-03-31 13F-HR TIGENIX SPONSORED ADS 88675R109 15.09 74,077 -4.01 1,156 2.76 -47 78 6.91
2016-12-31 13F-HR TIGENIX SPONSORED ADS 88675R109 77,174 1,125

Related SEC Filings

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D (Activist Investment)

2018-01-12 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668

TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D (Activist Investment)

2018-01-12 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668

Tigenix SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-07-13 sec.gov
Schedule 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.    )*     TiGenix   (Name of Issuer)         ordinary shares, no nominal value per share         (Title of Class of Securities)                 88675R 10 9                 (CUSIP Number)                 December 20, 2016                 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate t

Related News Stories

NCQ / NovaCopper Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-16 fintel.io
NovaCopper Inc. (AMEX:NCQ) has 42 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 42,442,992 shares. Largest shareholders include Paulson & Co. Inc., Baupost Group LLC/MA, South32 Ltd, Selz Capital LLC, Millennium Management Llc, Scoggin Llc, GMT Capital Corp, J. Goldman & Co LP, Renaissance Technologies LLC, and Manatuck Hill Partners, LLC. (20-0)

CIO / City Office REIT Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-15 fintel.io
City Office REIT Inc. (NYSE:CIO) has 145 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 24,888,328 shares. Largest shareholders include Principal Real Estate Investors Llc, Principal Financial Group Inc, Real Estate Management Services Llc, BlackRock Inc., Vanguard Group Inc, Renaissance Technologies LLC, Nuveen Asset Management, LLC, Lsv Asset Management, Millennium Management Llc, and Kennedy Capital Management, Inc. (34-0)

AKTS / Akoustis Technologies, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-15 fintel.io
Akoustis Technologies, Inc. (NASDAQ:AKTS) has 41 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,381,745 shares. Largest shareholders include Shealy Jeffrey B., Tompkins Mark N., Herald Investment Management Ltd, Vanguard Group Inc, BlackRock Inc., Millennium Management Llc, State Street Corp, Northern Trust Corp, D. (49-0)

FMSA / Fairmount Santrol Holdings Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-14 fintel.io
Fairmount Santrol Holdings Inc. (NYSE:FMSA) has 197 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 172,807,998 shares. Largest shareholders include Unimin Corp, Hartland & Co., LLC, Point72 Asset Management, L.P., Vanguard Group Inc, BlackRock Inc., State Street Corp, SailingStone Capital Partners LLC, TPH Asset Management, LLC, Barrow Hanley Mewhinney & Strauss Llc, and Millennium Management Llc. (59-0)

ACRX / AcelRx Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-14 fintel.io
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has 64 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 16,840,172 shares. Largest shareholders include Three Arch Partners Iv Lp, Vanguard Group Inc, Perceptive Advisors Llc, Palo Alto Investors, LLC, BlackRock Inc., Millennium Management Llc, Bridgeway Capital Management Inc, Geller Family Office Services, LLC, Susquehanna International Group, Llp, and Geode Capital Management, Llc. (99-3)

Bone Therapeutics: In (Re)Search For Money

2018-01-31 seekingalpha
On October 31, I released a focus article on Bone Therapeutics (OTC:BNZPF). On one hand, I was fairly excited about the crucial phase III interim results on osteonecrosis that are expected in H2 2018. On the other hand, I also warned investors on the less comfortable cash position of the company. In my previous estimates, I presumed a cash runway until May 2018. This article is intended to discuss recent developments concerning the company's cash position.

Takeda's Offer On Tigenix - Good Deal Or Not?

2018-01-12 seekingalpha
On the 5th of January, shareholders of TiGenix (NASDAQ:TIG) (OTC:TGXSF) were delighted with an unexpected treat. Japanese based medicine maker Takeda (OTCPK:TKPYY) (OTCPK:TKPHF) announced its intentions to acquire the Belgium-based biotech company. Takeda is offering €1.78 per share (~$2.14) - a premium of roughly 82% based on the last closing price of €0.98. This article intends to assess the bid.




CUSIP: 88675R109